Metsera, INC

Pfizer Inc. has finalized its acquisition of Metsera, Inc., converting Metsera shares into cash and contingent value rights, leading to its delisting from Nasdaq.

Metsera, Inc. and Pfizer Inc. amend their merger agreement, increasing the upfront cash consideration to $65.60 per share while adjusting contingent value rights.

Metsera announced a favorable ruling from the Delaware Court of Chancery, denying Pfizer's request for a temporary restraining order in their ongoing litigation related to the proposed acquisition.

Metsera's Board of Directors has determined that Novo Nordisk's revised acquisition proposal, valued at up to $86.20 per share, constitutes a Superior Company Proposal compared to Pfizer's offer.

Metsera, Inc. issued a strong statement rejecting Pfizer's litigation as an attempt to lower its acquisition price, vowing to defend shareholder interests.

Metsera, Inc. has issued a statement disagreeing with allegations in litigation filed by Pfizer Inc., which relates to Pfizer's proposed acquisition of Metsera and an unsolicited proposal from Novo Nordisk A/S.

Metsera reports significant losses and increased R&D expenses in Q3 2025, while its $10 billion acquisition by Pfizer progresses, despite ongoing shareholder and antitrust litigation.

Metsera, a clinical-stage biotechnology company, reported increased operating losses driven by significant research and development investments in its obesity and metabolic disease pipeline, while maintaining a robust cash balance following its recent initial public offering.

Metsera, a clinical-stage biopharmaceutical company, announces its first quarter 2025 financial results, emphasizing progress in its clinical programs for obesity and metabolic diseases.

Metsera's 2024 10-K filing highlights clinical advancements in its obesity and overweight therapies, alongside strategic manufacturing initiatives.

FMR LLC reports the disposition of Metsera, Inc. common stock following its acquisition by Pfizer Inc. for $65.60 cash per share plus a contingent value right.

ARCH Venture Partners entities and associated individuals reported the disposition of Metsera, Inc. common stock following its acquisition by Pfizer Inc. for $65.60 cash per share plus a CVR.

Metsera's Chief Medical Officer, Steven Marso, disposed of all common stock, restricted stock units, and stock options following the company's acquisition by Pfizer Inc. for $65.60 per share plus contingent value rights.

Paul L. Berns, a director of Metsera, Inc., reported the disposition of all his direct and indirect beneficial ownership in Metsera common stock, restricted stock units, and stock options following the company's merger with Pfizer Inc. on November 13, 2025.

Metsera, Inc. Chief Legal Officer Matthew Lang's equity holdings converted into cash and contingent value rights following the company's acquisition by Pfizer Inc.

Population Health Partners GP, LLC reported the disposition of all its Metsera, Inc. common stock following the company's merger with a Pfizer Inc. subsidiary for $65.60 per share cash and a contingent value right.

Metsera's Board unanimously recommends an amended merger agreement with Pfizer, increasing the cash consideration to $65.60 per share and total potential value to $86.25 per share, following a competitive bidding process and regulatory scrutiny.

Metsera's Board of Directors has determined that Novo Nordisk's revised acquisition proposal, valuing the company at up to $86.20 per share, constitutes a superior offer compared to Pfizer's latest proposal.

Metsera, Inc. issued a statement refuting Pfizer's litigation, asserting it is an attempt to lower the acquisition price amidst a competing proposal from Novo Nordisk.

Metsera, Inc. has issued a statement disagreeing with Pfizer's litigation allegations, vowing to address them in court.

Metsera's Board of Directors has deemed an unsolicited acquisition proposal from Novo Nordisk, valued at up to $77.75 per share, a 'Superior Company Proposal' compared to its existing merger agreement with Pfizer.

Metsera's Board unanimously recommends stockholders approve the merger with Pfizer for $47.50 cash plus a contingent value right up to $22.50 per share, valuing the deal at a 110% premium.

Metsera, Inc. has filed an amended and restated bylaws document detailing procedures for stockholder meetings, director nominations, and corporate governance ahead of its initial public offering.

Metsera, a clinical-stage biotech, is going public to fund its innovative pipeline of injectable and oral NuSH analog peptides targeting obesity and overweight, seeking to overcome limitations of existing treatments.

ARCH Venture Funds and associated individuals ceased to be 5% beneficial owners of Metsera, Inc. following its acquisition by Pfizer Inc. for $65.60 cash per share plus a contingent value right.

ARCH Venture Funds and affiliated entities have disclosed a substantial beneficial ownership of 25.5% in Metsera, Inc. common stock, acquired through a series of preferred stock conversions and recent IPO purchases for investment purposes.

Janus Henderson Group plc has reported a 3.1% beneficial ownership stake in Metsera, Inc. common stock through its various asset managers.

FMR LLC and Abigail P. Johnson have reported a complete divestment of their beneficial ownership in METSERA INC, reducing their stake to 0%.

Janus Henderson Group plc has reported a 5.1% beneficial ownership stake in METSERA, INC., held for investment purposes.

Metsera, Inc. has become a wholly-owned subsidiary of Pfizer Inc., with shareholders receiving $65.60 per share in cash and contingent value rights.

The Vanguard Group has reported a 5.53% beneficial ownership stake in Metsera Inc., holding 5,824,993 shares of common stock as of September 30, 2025.

A group of investors, including Validae Health, L.P. and key individuals, has disclosed beneficial ownership of 12.2% to 12.5% of Metsera, Inc.'s common stock as of March 31, 2025.